Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas. Bloomberg's Gerry Smith reports. (Source: Bloomberg)
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas. Bloomberg's Gerry Smith reports. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/091a5605c769540baff5b9af8d978cd07117c896" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Lilly Gets Back Into the Vaccine Business With New Deals"></iframe>
